Aerobic Exercise Performance and Muscle Strength in Statin Users-The LIFESTAT Study

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Aerobic Exercise Performance and Muscle Strength in Statin Users-The LIFESTAT Study. / Morville, Thomas; Dohlmann, Tine Lovso; Kuhlman, Anja Birk; Sahl, Ronni Eg; Kriegbaum, Margit; Larsen, Steen; Dela, Flemming; Helge, Jorn Wulff.

In: Medicine and Science in Sports and Exercise, Vol. 51, No. 7, 2019, p. 1429-1437.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Morville, T, Dohlmann, TL, Kuhlman, AB, Sahl, RE, Kriegbaum, M, Larsen, S, Dela, F & Helge, JW 2019, 'Aerobic Exercise Performance and Muscle Strength in Statin Users-The LIFESTAT Study', Medicine and Science in Sports and Exercise, vol. 51, no. 7, pp. 1429-1437. https://doi.org/10.1249/MSS.0000000000001920

APA

Morville, T., Dohlmann, T. L., Kuhlman, A. B., Sahl, R. E., Kriegbaum, M., Larsen, S., ... Helge, J. W. (2019). Aerobic Exercise Performance and Muscle Strength in Statin Users-The LIFESTAT Study. Medicine and Science in Sports and Exercise, 51(7), 1429-1437. https://doi.org/10.1249/MSS.0000000000001920

Vancouver

Morville T, Dohlmann TL, Kuhlman AB, Sahl RE, Kriegbaum M, Larsen S et al. Aerobic Exercise Performance and Muscle Strength in Statin Users-The LIFESTAT Study. Medicine and Science in Sports and Exercise. 2019;51(7):1429-1437. https://doi.org/10.1249/MSS.0000000000001920

Author

Morville, Thomas ; Dohlmann, Tine Lovso ; Kuhlman, Anja Birk ; Sahl, Ronni Eg ; Kriegbaum, Margit ; Larsen, Steen ; Dela, Flemming ; Helge, Jorn Wulff. / Aerobic Exercise Performance and Muscle Strength in Statin Users-The LIFESTAT Study. In: Medicine and Science in Sports and Exercise. 2019 ; Vol. 51, No. 7. pp. 1429-1437.

Bibtex

@article{8920fc5c88044734b33ced577ad1bfec,
title = "Aerobic Exercise Performance and Muscle Strength in Statin Users-The LIFESTAT Study",
abstract = "Introduction Statins are widely used in both primary and secondary prevention of cardiovascular disease. The treatment increases the risk of muscle pain (myalgia) which can affect muscle function and levels of physical activity. We investigated whether statin-associated myalgia is coupled to impaired aerobic exercise performance including fat oxidation as well as impaired muscle strength. Methods A population-based survey (6000 people) was performed to assess the prevalence of statin-associated myalgia in the Danish population. In addition, 64 statin users in primary prevention with myalgia (M; n = 25; 61 +/- 1 yr) or without myalgia (NM; n = 37; 63 +/- 1 yr) as well as a control group not taking statins (C; n = 20; 60 +/- 2 yr) were enrolled in a cross-sectional study where they performed aerobic exercise and muscle strength tests. Results The response rate for the survey was 51{\%} and data showed a prevalence of statin-associated myalgia in 19{\%} of responders using statins. The experimental study showed no difference between the groups in aerobic capacity (C, 29 +/- 1 mL O-2 center dot min(-1)center dot kg(-1); M, 27 +/- 1 mL O-2 center dot min(-1)center dot kg(-1); NM, 28 +/- 1 mL O-2 center dot min(-1)center dot kg(-1)) or maximal fat oxidation (C, 247 +/- 26 mg center dot min(-1); M, 295 +/- 24 mg center dot min(-1); NM, 279 +/- 17 mg center dot min(-1)). Measurements of strength were similar in all three groups including rate of force development (C, 795 +/- 56 N center dot m center dot s(-1); M, 930 +/- 93 N center dot m center dot s(-1); NM, 971 +/- 57 N center dot m center dot s(-1)) and leg extension power (C: 2.6 +/- 0.2; M: 2.3 +/- 0.1; NM: 2.4 +/- 0.1 W center dot kg(-1)). All results are mean +/- SEM. Conclusion Statin users in primary prevention experiencing myalgia do not have impaired aerobic exercise performance or muscle strength compared to nonmyalgic statin users or control subjects.",
keywords = "STATINS, CHOLESTEROL, AEROBIC CAPACITY, STRENGTH, MYALGIA",
author = "Thomas Morville and Dohlmann, {Tine Lovso} and Kuhlman, {Anja Birk} and Sahl, {Ronni Eg} and Margit Kriegbaum and Steen Larsen and Flemming Dela and Helge, {Jorn Wulff}",
year = "2019",
doi = "10.1249/MSS.0000000000001920",
language = "English",
volume = "51",
pages = "1429--1437",
journal = "Medicine and Science in Sports and Exercise",
issn = "0195-9131",
publisher = "Lippincott Williams & Wilkins",
number = "7",

}

RIS

TY - JOUR

T1 - Aerobic Exercise Performance and Muscle Strength in Statin Users-The LIFESTAT Study

AU - Morville, Thomas

AU - Dohlmann, Tine Lovso

AU - Kuhlman, Anja Birk

AU - Sahl, Ronni Eg

AU - Kriegbaum, Margit

AU - Larsen, Steen

AU - Dela, Flemming

AU - Helge, Jorn Wulff

PY - 2019

Y1 - 2019

N2 - Introduction Statins are widely used in both primary and secondary prevention of cardiovascular disease. The treatment increases the risk of muscle pain (myalgia) which can affect muscle function and levels of physical activity. We investigated whether statin-associated myalgia is coupled to impaired aerobic exercise performance including fat oxidation as well as impaired muscle strength. Methods A population-based survey (6000 people) was performed to assess the prevalence of statin-associated myalgia in the Danish population. In addition, 64 statin users in primary prevention with myalgia (M; n = 25; 61 +/- 1 yr) or without myalgia (NM; n = 37; 63 +/- 1 yr) as well as a control group not taking statins (C; n = 20; 60 +/- 2 yr) were enrolled in a cross-sectional study where they performed aerobic exercise and muscle strength tests. Results The response rate for the survey was 51% and data showed a prevalence of statin-associated myalgia in 19% of responders using statins. The experimental study showed no difference between the groups in aerobic capacity (C, 29 +/- 1 mL O-2 center dot min(-1)center dot kg(-1); M, 27 +/- 1 mL O-2 center dot min(-1)center dot kg(-1); NM, 28 +/- 1 mL O-2 center dot min(-1)center dot kg(-1)) or maximal fat oxidation (C, 247 +/- 26 mg center dot min(-1); M, 295 +/- 24 mg center dot min(-1); NM, 279 +/- 17 mg center dot min(-1)). Measurements of strength were similar in all three groups including rate of force development (C, 795 +/- 56 N center dot m center dot s(-1); M, 930 +/- 93 N center dot m center dot s(-1); NM, 971 +/- 57 N center dot m center dot s(-1)) and leg extension power (C: 2.6 +/- 0.2; M: 2.3 +/- 0.1; NM: 2.4 +/- 0.1 W center dot kg(-1)). All results are mean +/- SEM. Conclusion Statin users in primary prevention experiencing myalgia do not have impaired aerobic exercise performance or muscle strength compared to nonmyalgic statin users or control subjects.

AB - Introduction Statins are widely used in both primary and secondary prevention of cardiovascular disease. The treatment increases the risk of muscle pain (myalgia) which can affect muscle function and levels of physical activity. We investigated whether statin-associated myalgia is coupled to impaired aerobic exercise performance including fat oxidation as well as impaired muscle strength. Methods A population-based survey (6000 people) was performed to assess the prevalence of statin-associated myalgia in the Danish population. In addition, 64 statin users in primary prevention with myalgia (M; n = 25; 61 +/- 1 yr) or without myalgia (NM; n = 37; 63 +/- 1 yr) as well as a control group not taking statins (C; n = 20; 60 +/- 2 yr) were enrolled in a cross-sectional study where they performed aerobic exercise and muscle strength tests. Results The response rate for the survey was 51% and data showed a prevalence of statin-associated myalgia in 19% of responders using statins. The experimental study showed no difference between the groups in aerobic capacity (C, 29 +/- 1 mL O-2 center dot min(-1)center dot kg(-1); M, 27 +/- 1 mL O-2 center dot min(-1)center dot kg(-1); NM, 28 +/- 1 mL O-2 center dot min(-1)center dot kg(-1)) or maximal fat oxidation (C, 247 +/- 26 mg center dot min(-1); M, 295 +/- 24 mg center dot min(-1); NM, 279 +/- 17 mg center dot min(-1)). Measurements of strength were similar in all three groups including rate of force development (C, 795 +/- 56 N center dot m center dot s(-1); M, 930 +/- 93 N center dot m center dot s(-1); NM, 971 +/- 57 N center dot m center dot s(-1)) and leg extension power (C: 2.6 +/- 0.2; M: 2.3 +/- 0.1; NM: 2.4 +/- 0.1 W center dot kg(-1)). All results are mean +/- SEM. Conclusion Statin users in primary prevention experiencing myalgia do not have impaired aerobic exercise performance or muscle strength compared to nonmyalgic statin users or control subjects.

KW - STATINS

KW - CHOLESTEROL

KW - AEROBIC CAPACITY

KW - STRENGTH

KW - MYALGIA

U2 - 10.1249/MSS.0000000000001920

DO - 10.1249/MSS.0000000000001920

M3 - Journal article

VL - 51

SP - 1429

EP - 1437

JO - Medicine and Science in Sports and Exercise

JF - Medicine and Science in Sports and Exercise

SN - 0195-9131

IS - 7

ER -

ID: 223507154